Resilience Lab

Resilience Lab operated in the mental health services segment, combining virtual and in-person therapy, psychiatric medication management, clinician matching, and continuing education. Its stated differentiation was organizational rather than purely technological: the company focused on helping clinicians collaborate to deliver personalized and accessible care. Resilience Lab’s product breadth was broader than a single teletherapy offering, with care coordination and the Resilience Institute continuing education program extending beyond direct treatment delivery. The 2025 acquisition by Cerebral materially changed its competitive context: Resilience Lab’s capabilities became part of a larger mental health platform rather than remaining an independent venture.

Resilience Lab’s trajectory shows expansion from a clinician-collaboration concept founded in 2019 into a broader behavioral health services platform. The company announced a Seed round on Aug 3, 2021 and followed with a $15 million Series A on Nov 17, 2022, led by Morningside and Viewside Capital Partners. During 2022, it expanded its leadership bench with Patrick Morselli as COO, John Hamby as VP of Operations, and Alyssa Lin as Head of Growth, while Itai Preis served as CTO. Its offering covered therapy, psychiatric medication management, care coordination, and clinician education, suggesting an effort to build both a care-delivery network and supporting infrastructure. The Oct 8, 2024 acquisition of Options MD represented another step toward service expansion. The key inflection point came on Aug 4, 2025, when Cerebral acquired Resilience Lab in an all-stock transaction. That event shifted the company from venture-backed standalone growth to integration within a larger behavioral health platform. Clinical hiring activity was still noted, but the organization is now listed as closed, and there is insufficient public information to determine its post-acquisition headcount, product roadmap, or independent growth rate.